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There is no medication specifically approved for the
treatment of bipolar disorder not otherwise specified
(BD-NOS), substance-induced mood disorders and
mood disorders due to a general medical condition.
We report the case of a man whose post-transplant
BD-NOS was treated successfully with quetiapine.
Mr G, a 58-year-old man with cystic fibrosis and no
history of psychiatric disorders, as documented by a
pre-transplant SCID evaluation, received lung trans-
plantation in December 2004. The patient underwent
the post-transplant course with no medical or psychi-
atric complications until 6 wk after the transplant,
when he developed decreased need for sleep, eu-
phoria, irritability, grandiosity, pressured speech,
flights of ideas, increased sexual drive, mystical and
grandiose delusions. His symptoms led him to a poor
adherence to the post-transplant immunosuppressant
treatment and to other dangerous behaviours such as
not wearing the facemask and having sexual inter-
course despite medical advice to the contrary. A di-
agnosis of bipolar I disorder was deemed unlikely,
given the age of the patient, the absence of any family
and personal history of mood disorders and/or sui-
cide attempts, and the clinical situation in which the
symptoms developed. This impression was reinforced
by absence of any mood disorders symptoms during
the 2 years’ observation that followed the resolution
of the manic syndrome. At the time of the onset of
the symptoms described above, the patient’s treat-
ment included cyclosporine 350 mg/d, prednisone
25 mg/d, furosemide 25 mg/d, aciclovir 600 mg/d,
trimethoprim/sulfamethoxazole 160/800 mg every
other day, calcium levofolinate pentahydrate 7.5 mg/
d, omeprazole 20 mg/d, acetylsalicylic acid 100 mg/d.
We originally made a diagnosis of a corticosteroid-
induced mood disturbance with manic features.
However, upon a more thorough revision of the spe-
cific case, we revised our own diagnosis. In fact : (1) the
patient had been on steroids for a long period prior
to the transplant without any sign or symptom of
mania; (2) a role of the other medications and/or of
the patient’s general medical condition and/or of the
transplantation itself could not be ruled out; (3) we
could not exclude that he had under-reported some
symptoms, out of concerns of being deemed ineligible
for the transplantation; (4) he endorsed isolated traits
of hyperthymic temperament. Therefore, we diag-
nosed him with BD-NOS, based on the DSM provision
that permits formulation of this diagnosis in the case
of ‘situations in which the clinician has concluded that
a bipolar disorder is present but is unable to determine
whether it is primary, due to a general medical con-
dition, or substance induced’. We prescribed quetia-
pine. An atypical antipsychotic was preferred over a
classic mood stabilizer because of several factors in-
cluding: the presence of psychotic symptoms, the risk
of an interaction between corticosteroids and lithium,
via corticosteroid-induced changes in sodium balance,
and the risk of interactions between carbamazepine
and his other medications. Quetiapine was started at
50 mg/d and titrated up to 200 mg/d by day 4. The
patient’s psychiatric symptoms gradually improved,
until complete resolution 1 wk after reaching 200 mg/
d. The patient was maintained on quetiapine for
6 months, and then switched to divalproex because of
complaints of somnolence and difficulties with erec-
tion that he attributed to quetiapine. The decision to
continue the anti-manic treatment after the resolution
of his psychiatric symptoms was primarily due to the
fact that he needed to continue taking the immuno-
suppressants. However, the patient discontinued
divalproex of his own accord after 24 wk of treatment
and, as of July 2007, he is still symptom free.
This case suggests the potential efficacy of quetia-
pine in mood disorders induced by a medication or by
a medical condition and highlights the diagnostic dif-
ficulties for cases such as the one we have described.
We hope that DSM-V will maintain the diagnosis
of BD-NOS or provide better diagnostic categories/
criteria for situations similar to the case that we have
reported.
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